Atria Investments Inc Sells 1,773 Shares of Hologic, Inc. $HOLX

Atria Investments Inc decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 7.7% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 21,221 shares of the medical equipment provider’s stock after selling 1,773 shares during the quarter. Atria Investments Inc’s holdings in Hologic were worth $1,383,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Chung Wu Investment Group LLC bought a new stake in Hologic during the second quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd boosted its position in Hologic by 193.6% during the second quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares during the period. Zions Bancorporation National Association UT bought a new stake in Hologic during the first quarter worth approximately $34,000. Cromwell Holdings LLC boosted its position in Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 436 shares during the period. Finally, Allworth Financial LP boosted its position in Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 216 shares during the period. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of NASDAQ HOLX opened at $74.23 on Thursday. The business has a fifty day simple moving average of $68.70 and a 200 day simple moving average of $64.93. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $16.51 billion, a price-to-earnings ratio of 30.80, a PEG ratio of 2.54 and a beta of 0.65. Hologic, Inc. has a one year low of $51.90 and a one year high of $81.13.

Hologic (NASDAQ:HOLX) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating analysts’ consensus estimates of $1.10 by $0.03. The business had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.03 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.01 earnings per share. Sell-side analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on HOLX shares. Wall Street Zen cut Hologic from a “buy” rating to a “hold” rating in a research report on Wednesday, October 1st. Mizuho cut Hologic from an “outperform” rating to a “neutral” rating and upped their target price for the stock from $70.00 to $78.00 in a research report on Thursday, October 23rd. Royal Bank Of Canada raised Hologic from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $72.00 to $87.00 in a research report on Wednesday, August 6th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $78.00 price target on shares of Hologic in a report on Wednesday, October 22nd. Finally, Citigroup upgraded Hologic from a “neutral” rating to a “buy” rating and upped their price target for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and thirteen have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $79.23.

Insiders Place Their Bets

In related news, Director Christiana Stamoulis sold 7,402 shares of the company’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the transaction, the director directly owned 47,336 shares in the company, valued at approximately $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 1.88% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.